AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
AstraZeneca PLC (AZN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
AstraZeneca PLC Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - AZN
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Levi & Korsinsky Reminds Shareholders of an Investigation into AstraZeneca PLC (AZN) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
AstraZeneca hits out at NICE block to breast cancer drug
AstraZeneca PLC (LSE:AZN) and Daiichi Sankyo said they are 'disappointed and disagree' with a decision by the UK medicines regulator not to give the green light to a breast cancer drug they jointly developed. Talks to approve Enhertu for NHS used collapsed over pricing and despite the intervention of Wes Streeting, the health secretary.
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free survival by more than three years in certain NSCLC patients.
Goldman: Buy British for better returns in 2025
In its latest outlook for 2025, Goldman Sachs is urging investors to “buy British” as undervalued UK stocks offer an attractive opportunity in Europe's otherwise tepid equity market. The bank highlights that UK shares, particularly those with a domestic focus, are trading at a discount compared to other European and US markets.
AstraZeneca PLC Being Investigated on Behalf of AstraZeneca PLC Investors, Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
